Press

17 Jun Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma.

Posted at 11:38h in News, Press, Uncategorized

140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. Laminar Pharmaceuticals S.A., a clinical-stage biotechnological company developing novel therapies...

06 Mar Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma.

Posted at 08:10h in News, Press, Uncategorized

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its open readout at 66 progression...

10 Mar The Universidad de Alicante Science Park boosts its biotechnology cluster with the addition of Laminar Pharma

Posted at 17:01h in Press

Alicante Science Park Foundation (PCA) and Laminar Pharmaceuticals have signed today the contract by which the biotechnology company is linked to the PCA....

08 Mar Laminar Pharma’s researcher in oncology, Gema Malet, receives a Marie Skłodowska-Curie research grant in recognition of her excellent professional development

Posted at 11:49h in Press

In 2020, biologist Gema Malet Engra joined the biotechnology company Laminar Pharmaceuticals after a successful 15-year career in fundamental and applied research in Oncology at several international research centers. ...

12 Feb Laminar Pharma will host a postdoctoral project to isolate protumoral proteins thanks to funding from the Government of the Balearic Islands

Posted at 10:06h in Press

On January 2021, the researchers whose projects have received funding from the CAIB 2020 call of the Balearic Government for the promotion of hiring of research staff were announced: Ramón Román Roldán has been selected, and he will join the Research Unit of Laminar Pharma....

10 Dec Biotechnology company Laminar Pharma, finalist in the 5th CAEB Santander Awards for Business Innovation

Posted at 15:52h in Press

The ceremony for the 5th edition of the Awards of the Confederation of Business Associations of the Balearic Islands (CAEB), called CAEB SANTANDER, was held today in Palma de Mallorca, to recognize the business innovation of small and medium-sized companies....

01 Dec Laminar Pharma announces that it will reach 1.2M euros with its latest round of financing

Posted at 18:18h in Press

One week before closing the funding round, the company has surpassed 90% of the target figure.The funding round is managed through the Fellow Funders Crowd Investment platform and is part of the preparations prior to Laminar joining BME Growth.The company's stock market debut on BME Growth (formerly Alternative Stock...

20 Nov Spanish biotech company Laminar, the Fundación Rioja Salud and the University of the Balearic Islands will receive one million euros from the Ministry of Science and Innovation to study brain tumor biomarkers

Posted at 10:45h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text] From the left, top: Adrian McNicholl, Gema Malet, Pablo V. Escribá, Ignacio Larrayoz, Paula Fernández y Roberto Beteta. Seated: Emilce Cano, Rafael Peláez, Catalina Rosselló, Raquel Rodríguez y Manuel Torres. November 20th, 2020 The Spanish government has announced...

22 Jul Spanish biotechnology company Laminar Pharma joins the Growth segment of the Pre-Market Environment, in a step towards joining the stock market

Posted at 09:59h in Press, Sin categoría

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Given the good track record of the stock market as an alternative source of financing, the biotechnology company Laminar Pharma is taking its first steps to attract private investors and institutions, by joining...

03 Jun (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity

Posted at 13:54h in Documents, Press

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="grid" angled_section="no" text_align="left" background_image_as_pattern="without_pattern" z_index="" padding_bottom="120"][vc_column width="5/6"][vc_separator type="transparent" up="35"][vc_column_text]Massalha W, et al. Minerval (2-hydroxyoleic acid) causes cancer cell selective toxicity by uncoupling oxidative phosphorylation and compromising bioenergetic compensation capacity. Biosci Rep. 2019 Jan 18;39(1). pii: BSR20181661. doi: 10.1042/BSR20181661[/vc_column_text][vc_separator type="transparent" up="35"][/vc_column][vc_column width="1/6"][/vc_column][/vc_row]...